Welcome to
The Next Frontier in NTD Control: Implementing the Roadmap from the London Declaration’s 2020 Goals

April 11, 2012
The NTD Roadmap and USAID Support

Angela M. Weaver
Senior Advisor, USAID’s NTD Program
Neglected diseases (Hundreds)

Large DALY impact and available tools for control?

Tropical?

33 diseases

7 diseases

1. Ascaris*
2. Trichuris*
3. Hookworm*
4. Lymphatic filariasis
5. Onchocerciasis
6. Schistosomiasis
7. Trachoma

33 diseases recognized by WHO as NTDs including

- Ascaris
- Trichuris
- Hookworm
- Lymphatic filariasis
- Onchocerciasis
- Guinea worm
- Schistosomiasis
- Leishmaniasis
- Chagas disease
- African trypanosomiasis
- Dengue fever
- Leprosy
- Trachoma

* Soil transmitted helminths (STH)
<table>
<thead>
<tr>
<th>Lymphatic Filariasis</th>
<th>Onchocerciasis</th>
<th>Schistosomiasis</th>
<th>Soil Transmitted Helminthes</th>
<th>Trachoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>120 Million <em>Infected</em></td>
<td>37 Million <em>Infected</em></td>
<td>200 Million <em>Infected</em></td>
<td>800 Million <em>Infected</em></td>
<td>84 Million <em>Infected</em></td>
</tr>
<tr>
<td>1.2 Billion <em>at risk</em></td>
<td>0.15 Billion <em>at risk</em></td>
<td>0.7 Billion <em>at risk</em></td>
<td>1.2 Billion <em>at risk</em></td>
<td>1.2 Billion <em>at risk</em></td>
</tr>
</tbody>
</table>

- Painful disfiguring
- Stigmatizing
- Permanent disability
- Loss of productivity and income

- Severe visual impairment, including blindness
- Severe itching
- Loss of productivity and income

- Anemia, stunting in children
- Reduced ability to learn
- Chronic diseases (e.g., liver damage, bladder cancer, kidney failure)

- Growth retardation
- Malnutrition and iron deficiency anemia
- Impaired cognitive development

- Untreated leads to irreversible blindness

Preventive Chemotherapy NTDs
### Preventive Chemotherapy NTDs

<table>
<thead>
<tr>
<th></th>
<th>Lymphatic Filariasis</th>
<th>Onchocerciasis</th>
<th>Schistosomiasis</th>
<th>Soil Transmitted Helminthes</th>
<th>Trachoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs</td>
<td>Albendazole, Ivermectin, DEC</td>
<td>Ivermectin</td>
<td>Praziquantel</td>
<td>Albendazole, Mebendazole</td>
<td>Azithromycin</td>
</tr>
<tr>
<td>Companies</td>
<td>GlaxoSmithKline, Merck &amp; Co., Inc., Eisai</td>
<td>Merck &amp; Co., Inc.</td>
<td>Merck KGaA</td>
<td>Johnson &amp; Johnson, GlaxoSmithKline</td>
<td>Pfizer</td>
</tr>
</tbody>
</table>
Rationale for Integrated Approach

Conditions right for integrated approach

- Disease clusters
- Safe and effective treatments available for each disease
- Can be targeted through annual mass drug administration (+SAFE for trachoma)
- Most drugs donated by Pharmaceutical companies
- Drug delivery can be integrated at country level into existing platforms
The NTD Roadmap

ACCELERATING WORK TO OVERCOME THE GLOBAL IMPACT OF NEGLECTED TROPICAL DISEASES
A ROADMAP FOR IMPLEMENTATION

Available on the website of WHO department of Control of neglected tropical diseases: www.who.int/neglected_diseases

Direct URLs to access to the document and its Executive summary

Annexes with direct link to online databank of each disease

A roadmap for implementation on line: www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf
Executive summary online: http://whqlibdoc.who.int/hq/2012/WHO_HTM_NTD_2012.1_eng.pdf
Uniting to Combat Neglected Tropical Diseases
Ending the Neglect and Reaching 2020 Goals

View the Archived Webcast

Featuring Bill Gates, Margaret Chan, 9 pharmaceutical company CEOs, senior government officials and others
London | 30 January 2012

www.unitingtocombatntds.org
Success Breeds Success

Sequence

- Early disease-specific program support – public, private, corporate
- 2006: Congressional interest in NTDs – first USAID NTD earmark - ~$15 million in the first year
- 2006: Gates grants for NTD program implementation - ~$60 million
- 2007: Global Network (GNNTD) – Gates advocacy - $34 million
- 2008: Presidential Initiative (Bush) for NTDs – budget increases to $25 million for FY09
- 2009: G8 commitment to NTDs; UK commits ~$80 million
- 2009: Expanded Presidential Global Health Initiative (Obama) – highlights NTDs as a USG priority
- 2012: Increased UK commitment: ~$400 million over 4 years and USAID NTD budget increases to $89 million for FY12
- 2012: Increased Gates Foundation, World Bank, Pharma commitments
Success Breeds Success

Sequence

- Early disease-specific program support – public, private, corporate
- 2006: Congressional interest in *NTDs* – first USAID NTD earmark - ~$15 million in the first year
- 2006: Gates grants for *NTD* program implementation - ~$60 million
- 2007: Global Network (GNNTD) – Gates advocacy - $34 million
- 2008: Presidential Initiative (Bush) for *NTDs* – budget increases to $25 million for FY09
- 2009: G8 commitment to *NTDs*; UK commits ~$80 million
- 2009: Expanded Presidential Global Health Initiative (Obama) – highlights NTDs as a USG priority
- 2012: Increased UK commitment: ~$400 million over 4 years and USAID NTD budget increases to $89 million for FY12
- 2012: Increased Gates Foundation, World Bank, Pharma commitments
Evolution of the USAID NTD Program

First Phase (FY 06 – FY 11)
- Demonstrate success of integrated approach
- National Scale-up and Identification of Gaps
- Drive International Policy
- Assess Progress toward Targets
- Enhanced M&E Strategy

Second Phase (FY 12 - ?)
- Achieve Elimination and Control

The diagram illustrates the progression from the first phase (FY 06 – FY 11) to the second phase (FY 12 - ?) of the USAID NTD Program. It highlights key steps such as national scale-up, identification of gaps, driving international policy, assessing progress toward targets, and achieving elimination and control. Enhanced M&E strategy is also emphasized.
A Special Thanks…to all who work hard to make NTD programs possible
The Roadmap—Why Now?

Eric Ottesen, MD
Project Director, ENVISION, RTI International
## The Targeted NTDs

<table>
<thead>
<tr>
<th></th>
<th>LF</th>
<th>Oncho</th>
<th>Schisto</th>
<th>STH</th>
<th>Trachoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases</td>
<td>120 Million Infected</td>
<td>37 Million Infected</td>
<td>200 Million Infected</td>
<td>800 Million Infected</td>
<td>84 Million Infected</td>
</tr>
<tr>
<td>At risk</td>
<td>1.2 Billion at risk</td>
<td>0.4 Billion at risk</td>
<td>0.7 Billion at risk</td>
<td>1.2 Billion at risk</td>
<td>1.2 Billion at risk</td>
</tr>
</tbody>
</table>
The Roadmap – Why Now?

1) The pieces are coming together

*Health-speak*

**Targets identified**  **Strategies defined**  **Tools available**
The Roadmap – Why Now?

1) The pieces are coming together

Health-speak

- Targets identified
- Strategies defined
- Tools available

Metaphor-speak

- Destinations known
- Routes understood
- Fuel ready
The Roadmap – Why Now?

1) The pieces are coming together

*Health-speak*

- Targets identified
- Strategies defined
- Tools available

*Metaphor-speak*

- Destinations known
- Routes understood
- Fuel ready
The Roadmap – Why Now?

1) The pieces are coming together

*Health-speak*

Targets identified  Strategies defined  Tools available

*Metaphor-speak*

Destinations known  Routes understood  Fuel ready  Fleet of vehicles
The Roadmap – Why Now?

1) The pieces are coming together

**Health-speak**

- Targets identified
- Strategies defined
- Tools available

**Metaphor-speak**

- Destinations known
- Routes understood
- Fuel ready
- Fleet of vehicles
The Roadmap – Why Now?

1) The pieces are coming together

*Health-speak*

- Targets identified
- Strategies defined
- Tools available
- Implementation funds

*Metaphor-speak*

- Destinations known
- Routes understood
- Fuel ready
- Fleet of vehicles
Targeting the NTDs – Past History

- **River blindness** (onchocerciasis)
  - fueled by Merck’s Mectizan donation
  - implementation ensured by funds from WB, US + 19 other donors
  - *highly successful (health / economic) regionally*

- **Elephantiasis** (lymphatic filariasis [LF])
  - fueled by GSK’s albendazole and Merck’s Mectizan donations
  - implementation *mostly self-funded* by endemic countries (+ some from UK, Japan, Gates)
  - *highly successful (health / economic) where implemented*

- **Intestinal worms** (soil transmitted helminths [STH])
  - implementation through school-health & pre-school programs (MOE, UNICEF)
  - *highly successful where implemented*

- **Others** (schistosomiasis, trachoma)
  - *success at local, not global scale*
The Change

- Recognition that
  - all these diseases affect the same ‘bottom billion’
  - all are preventable / eliminatable by once-yearly donated, safe, effective drugs
  - programs targeting these NTDs should be ‘integrated’

- Gates Foundation (2005) invested in operational research to show feasibility of integrated / coordinated NTD programs

- US Congress (2006) appropriated 1st significant funding for implementation of ‘integrated‘ NTD programs at full national scale
The Roadmap – Why Now?

1) The pieces are coming together
The Roadmap – Why Now?

2) Success can be demonstrated

<table>
<thead>
<tr>
<th>Targets identified</th>
<th>Strategies defined</th>
<th>Tools available</th>
<th>Implementation funds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Destinations known</td>
<td>Routes understood</td>
<td>Fuel ready</td>
<td>Fleet of vehicles</td>
</tr>
</tbody>
</table>

The Challenge

- If you follow the roadmap and reach the destination, can you deliver?
- If implementation funds are put into the system, can you deliver?
USG Support Targeting NTDs

Support Accountability & Facilitation Implementation

MDA
- Single
- Multiple
- Fixed-post
- House/house

CHD+
- Single
- Multiple

CHD+ & MDA

CDTI
## Partner Countries and Lead NGOs

<table>
<thead>
<tr>
<th>NTD Control Program</th>
<th>Country</th>
<th>Lead NGO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fast-Track</strong></td>
<td>Burkina Faso</td>
<td>Schistosomiasis Control Initiative</td>
</tr>
<tr>
<td></td>
<td>Ghana</td>
<td>World Vision</td>
</tr>
<tr>
<td></td>
<td>Mali</td>
<td>Helen Keller International</td>
</tr>
<tr>
<td></td>
<td>Niger</td>
<td>Schistosomiasis Control Initiative</td>
</tr>
<tr>
<td></td>
<td>Uganda</td>
<td>RTI International</td>
</tr>
<tr>
<td><strong>Additional Countries</strong></td>
<td>Bangladesh</td>
<td>RTI International</td>
</tr>
<tr>
<td></td>
<td>Cameroon</td>
<td>Helen Keller International</td>
</tr>
<tr>
<td></td>
<td>Guinea</td>
<td>Helen Keller International</td>
</tr>
<tr>
<td></td>
<td>Haiti</td>
<td>IMA World Health</td>
</tr>
<tr>
<td></td>
<td>Indonesia</td>
<td>RTI International</td>
</tr>
<tr>
<td></td>
<td>Nepal</td>
<td>RTI International</td>
</tr>
<tr>
<td></td>
<td>Sierra Leone</td>
<td>Helen Keller International</td>
</tr>
<tr>
<td></td>
<td>Southern Sudan</td>
<td>Malaria Consortium</td>
</tr>
<tr>
<td></td>
<td>Tanzania</td>
<td>IMA World Health</td>
</tr>
<tr>
<td></td>
<td>Togo</td>
<td>Health and Development International</td>
</tr>
</tbody>
</table>
Partnering with WHO: the ‘Roll-out package’

- **Laying the groundwork**
  - Ensure government commitment
  - Perform a ‘situation analysis’
  - Create a POA
  - Assess the funding gap

- **Rolling out the program**
  - Convene stakeholder meetings
  - Develop a work plan
  - Map disease distribution
  - Define an M&E strategy
  - Initiate the MDA

- **Establishing management**
  - Agree on roles and responsibilities
  - Organize a national central coordinating mechanism
NTD Control Program Scale-Up: Years 1-5

13 countries
## Value of Donated Drugs Delivered to National NTD Programs in Year 5

<table>
<thead>
<tr>
<th>Country</th>
<th>TOTAL (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangladesh</td>
<td>$3,445,770</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>$180,232,835</td>
</tr>
<tr>
<td>Cameroon</td>
<td>$67,115,971</td>
</tr>
<tr>
<td>Ghana</td>
<td>$112,519,652</td>
</tr>
<tr>
<td>Guinea</td>
<td>$5,635,500</td>
</tr>
<tr>
<td>Haiti</td>
<td>$344,085</td>
</tr>
<tr>
<td>Indonesia</td>
<td>$832,500</td>
</tr>
<tr>
<td>Mali</td>
<td>$161,305,284</td>
</tr>
<tr>
<td>Nepal</td>
<td>$15,217,266</td>
</tr>
<tr>
<td>Niger</td>
<td>$253,557,763</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>$21,776,117</td>
</tr>
<tr>
<td>Southern Sudan</td>
<td>$16,775,250</td>
</tr>
<tr>
<td>Tanzania</td>
<td>$55,410,236</td>
</tr>
<tr>
<td>Togo</td>
<td>$12,250,144</td>
</tr>
<tr>
<td>Uganda</td>
<td>$42,488,896</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$948,907,267</strong></td>
</tr>
</tbody>
</table>
Over $3 billion worth of donated drugs delivered to NTD Control Program countries since 2006.
Yearly Donations for Programs Targeting the NTDs

USAID NTD Control Program

Tablets (millions)

- 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Albendazole
Mectizan

RTI International
2) Success can be demonstrated
3) **A window of opportunity**

- Utilize a strategy/roadmap already **proven successful** against the NTDs
- Work in **close partnership** between private and public sectors
- Leverage unique contributions of each partner

- **To achieve major developmental impact**
  - **Health improvement** - **proven**
  - **Education enhancement** - **proven**
  - **Economic advancement** - **proven**
  - **Social equity**

- **At extraordinarily low cost**
Comparative Treatment Costs (Range)

- **TB**: Ref: Global TB Control 2005
- **Malaria**: Ref: Chmia, 2003; Molyneux *et al* 2005
- **NTD Package**: Ref: Brady *et al* 2005
3) A window of opportunity

- The London Declaration: partnerships / commitments
  - Increased *recognition* of the scope of the NTD problem and effectiveness of the integrated programs
  - Expanded *private-sector* commitment
  - Expanded *national* commitments
    - Disease-endemic countries
    - Bilateral development agencies
  - Engagement of *international* agencies / World Bank commitments

- Highly favorable return-on-investment / cost-benefit
1) The pieces have come together
2) Success has been demonstrated
3) A window of opportunity has opened
Case Study: How expansion and integration of NTD programs has accelerated elimination of blinding trachoma

11th April 2012
Paul Emerson PhD., MSc., BSc.
Director Trachoma Control Program,
Co-Director Malaria Control Program
The Carter Center, Atlanta
Trachoma is an NTD that causes blindness.
The elimination of blinding trachoma is through an integrated strategy with four pillars:

- **Surgery**
- **Antibiotics**
- **Facial cleanliness**
- **Environmental Improvement**
Prevalence of active trachoma, baseline ‘97-’98
Districts receiving MDA, 2003
Districts receiving MDA, 2009
Prevalence of active trachoma, 2011
Meeting the Challenges that Lie Ahead: Technical, Financial and Political

Julie Jacobson MD DTMH
Bill & Melinda Gates Foundation
January 30th London

Uniting to Combat Neglected Tropical Diseases
Ending the Neglect and Reaching 2020 Goals

Secret is shared common goals and worthy targets

http://www.youtube.com/watch?v=EZ8rvOiKDuI&feature=youtu.be
Where we are now
Where we can get with existing tools and strategies
Where we can get with new tools and strategies

Diseases Targeted For Elimination

- Guinea worm
- Leprosy
- Lymphatic filariasis
- Blinding trachoma
- Sleeping sickness

Diseases Targeted For Control

- Schistosomiasis
- River blindness
- Soil-transmitted
- Chagas disease
- Visceral leishmaniasis

2020 Goals
After the Event

The work begins

- Not about creating a huge new organization-stay lean, get organized, stay focused, and work with what is there
- Share the targets and communicate
- Follow progress, anticipate gaps, and course correct
- Get additional and expanded political, financial and technical support
Global organizational arrangement in support of country lead NTD control and elimination efforts

Global NTD partners

broad innovative partnership with a shared commitment to the NTD 2020 goals: open membership to interested parties with subgroups as needed building on the London Declaration
## Milestone Table

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Trachoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Schisto</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>STH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Oncho</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Leprosy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Chagas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Guinea worm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eradicate</td>
</tr>
<tr>
<td>HAT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>VL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
</tbody>
</table>
## Milestone Table

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Trachoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Schisto</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>STH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Oncho</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Leprosy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Chagas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Guinea worm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eradicate</td>
</tr>
<tr>
<td>HAT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>VL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
</tbody>
</table>
# Milestone Table

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Trachoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Schisto</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>STH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Oncho</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Leprosy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
<tr>
<td>Chagas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>Guinea worm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eradicate</td>
</tr>
<tr>
<td>HAT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>control</td>
</tr>
<tr>
<td>VL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>eliminate</td>
</tr>
</tbody>
</table>
How to follow progress

Global NTD Milestone Table

Pharma scorecard

NGO scorecard

Endemic country scorecard (WHO)

Funding scorecard

Partner A workplan and progress

Partner B workplan and progress

NGO A workplan and progress

NGO B workplan and progress

Endemic country national plan and indicators

Endemic country national plan and indicators

Donor commitments and payout

Fundraiser progress
Global organizational arrangement in support of country lead NTD control and elimination efforts

Global NTD partners: broad innovative partnership with a shared commitment to the NTD 2020 goals:

- Technical Subgroup
  - UN agencies
  - NGOs
  - Academic and technical
- Donor Subgroup
  - Industry
  - Donors
- Advocacy and fundraising
  - media
  - Patient advocates
- Civil society subgroup
  - NGOs
  - Professional organizations
  - Intersectoral partners
Global organizational arrangement in support of country lead NTD control and elimination efforts

Global NTD partners: broad innovative partnership with a shared commitment to the NTD 2020 goals: open membership to interested parties with subgroups as needed building on the London Declaration

**Global NTD Coordination Committee:**

Key committed organizations representing different components of the partnership

- **Advocacy and fundraising:** GNNTD, END fund, IDB NTD
- **Civil society subgroup:** NTD NDGO Network (NNN)
- **Technical Subgroup:** can build on the ASTMH meeting
- **Donor Subgroup:** under discussion now Pharma/industry
Plans

• Develop the Global NTD Milestone Table
• Work across partners for the development of scorecards
• Plan communications options and feedback times-website, telecons, meetings

• Upcoming Meetings
  – WHO Geneva April 23-25\textsuperscript{th} - partner coordination and communication with the WHO NTD Strategic and Technical Advisory Group
  – November 17-20\textsuperscript{th} DC meeting of NTD partners and endemic countries
  – Dec 11-13\textsuperscript{th}, potential meeting in Burundi

• Engaging more partners- You are part of the team!
• http://unitingtocombatntds.org/
Thank you for attending

The Next Frontier in NTD Control: Implementing the Roadmap from the London Declaration’s 2020 Goals